see that physicians practising in centres of excellence remain enthusiastic about such techniques.
On the subject offlupenthixol, the ABPI Data Sheet Compendium 1987, states that; 'Clinical trials have shown symptoms of apathy, lowered mood, asthenia; despondency, lack of initiative and inertia are likely to respond well to flupenthixol and that its high therapeutic index is an advantage in view of the suicide risk associated with depressive illness.' My colleagues and I have used flupenthixol in mild depressive conditions in general practice at doses of 0.5-1 mg daily in short courses (usually lasting less than 6 weeks) and have found no problems with tardive dyskinesia. We would, of course, acknowledge that larger doses used for longer periods of time may lead to such problems. I feel, however, that our paper does highlight all these points and emphasizes the low dosage and the duration of courses of treatment. Any screening test should be cheap, specific and sensitive. As indicated by Flanagan et al. the determination of the anion gap by calculation has no intrinsic cost, but this only holds true if the population being screened is already having plasma electrolyte determinations for some other reason. It also assumes that plasma chloride is among the parameters being profiled, which is by no means always the case.
If a test has high specificity and sensitivity, by definition its use should result in few false positive and false negative categorizations. Any cause of hypoproteinaemia may be associated with a reduced anion gap in the absence of myeloma. In addition, the overlapping distributions of anion gaps in the healthy population and in patients with myeloma, and particularly those patients with IgA paraproteinaemia, would make it difficult to interpret a 'normal' result. Because the depressed anion gap, in some patients with myeloma, is in part dependent on the magnitude of the paraproteinaemia, early disease may easily be missed.
The authors mention other simple haematological screening tests for myeloma, including ESR and background staining as a blood film, but they fail to discuss the use of simple and cheap biochemical indices, such as the measurement of serum total protein and albumin.
Renal impairment is a common feature of malignant paraproteinaemia. The associated increase in anion gap would tend to off-set the reduction related to the myeloma, and would therefore be a cause for a false negative result. Flanagan et al. do not mention what proportion of their patient group was so affected.
Elderly subjects do indeed have a high prevalence of myeloma, and perhaps they should be screened for this disease. However, estimation of total serum protein and albumin, with a derived estimate of serum gamma-globulins, followed by serum protein electrophoresis and immunofixation, would appear to be the most logical diagnostic approach. suggest that the anion gap may be useful as a screening test for myeloma in the elderly, and that this procedure has no intrinsic cost.
The predictive value of a low anion gap for myeloma is not given, but can be calculated from published datal using Bayes' theorern'', The probability of myeloma in the general population of Cumbria is 0.00026 3 . If every patient with this disease has a low anion gap, this can be compared to the probability of a low anion gap occurring from other causes. A study of 39 360 patients' found a low anion gap at least once in 304 (probability=0.0077) including one case of myeloma. Thus the probability of a patient with a low anion gap having myeloma is 0.00026/0.0077, ie 0.034. Accordingly, 97% of patients with a low anion gap do not have myeloma and 'no intrinsic cost' becomes inflated by the 'need for more specific investigation'.
Multichannel continuous-flow analysers can produce a great deal of unsolicited data. Any procedure that extracts clinically useful information from this at no extra cost is worthwhile. The early diagnosis of myeloma is highly desirable. However, with a trend towards discretionary analysis, it is doubtful whether these figures justify the real cost of including the anion gap in a biochemical profile. T J DAVIES Assessment of self-poisoning patients by psychiatrists and junior medical staff Sir, The study of assessment in one particular casualty unit by Creed and Black (February 1988 JRSM, p 97) highlights the advantages and shortfalls in care of patients treated wholly in out-patient units as compared with those assessed while they are inpatients.
The challenge raised in the last paragraph could well be answered, to the advantage of all, by a nationwide duplication of the near-ideal system in Sunderland District General Hospital (catchment 350000 urban to 500 000 total, including hinterland) where all self-poisoning or self-harming patients are treated, for the acute situation, in the out-patient unit, swiftly admitted to the 22-bedded accident/emergency ward, maintained under (now fairly expert) ward nursing staff, and seen next day (or sooner if necessary) by the senior accident/emergency staff, consultants or senior registrars (that cadre which, on
